GO
Loading...

Enter multiple symbols separated by commas

Teva Pharmaceutical Industries Ltd

More

  • NEW YORK/ LONDON, June 29- Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007, according to preliminary Thomson Reuters data, as big companies turned to deals to boost their market share. These include Royal Dutch Shell Plc's $70 billion acquisition of British rival BG Group Plc, cable...

  • TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. Perrigo's shares have been listed on TASE since it acquired Israeli...

  • Mylan eyes Tel Aviv listing if Perrigo deal goes ahead Wednesday, 24 Jun 2015 | 9:07 AM ET

    TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. "Mylan believes that the Israeli market is important to Mylan and the...

  • TEL AVIV, June 23- Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said. Mylan has offered to acquire Perrigo for $34 billion in an attempt to fend off a bid from Israel's Teva...

  • LONDON, June 22- European private equity fund CVC and Singaporean sovereign wealth fund Temasek are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said. Robert Wessman, former CEO of Actavis, founded the New Jersey- based generic drugs firm in 2009.. The transaction is the latest sign of the hectic pace of...

  • LONDON, June 22- European private equity fund CVC and Singaporean sovereign wealth fund Temasek are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said. Robert Wessman, former CEO of Actavis, founded the New Jersey- based generic drugs firm in 2009.. The transaction is the latest sign of the hectic pace of...

  • NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. The decision, by the U.S. Court of Appeals for the Federal Circuit, the nation's top patent tribunal, was a blow to Israel's...

  • U.S. appeals court again invalidates Teva MS drug patent Thursday, 18 Jun 2015 | 11:56 AM ET

    NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version.

  • June 16- Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend of interest from Teva Pharmaceutical Industries Ltd. Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's "standalone strategy" and believed acquiring Perrigo...

  • Abbott to vote for Mylan's acquisition of Perrigo Tuesday, 16 Jun 2015 | 9:20 AM ET

    June 16- Abbott Laboratories said it would vote its 14.5 percent stake in Mylan NV in favor of Mylan's proposed acquisition of Perrigo Company Plc. Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs. Abbott, Mylan's largest shareholder, said...

  • UPDATE 1-Teva switches legal counsel after Mylan challenge Wednesday, 10 Jun 2015 | 12:41 AM ET

    June 9- Teva Pharmaceutical Industries Ltd has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm. Teva is now working with Sullivan& Cromwell LLP as legal counsel in its proposal to acquire Mylan, the...

  • June 5- Orexigen Therapeutics Inc and partner Takeda Pharmaceutical Co Ltd said they had filed a lawsuit against Actavis Plc to block a generic version of diet-pill Contrave. The lawsuit, filed at a Delaware district court, alleges that Actavis has infringed patents on Orexigen and Takeda's weight-loss treatment. Actavis and Teva Pharmaceutical Industries...

  • These are the best stocks from now to October Tuesday, 2 Jun 2015 | 10:56 AM ET
    Healthcare

    Since 1990 this stock sector has risen 5.2 percent. It's outperformed the broader market 65 percent of the time from May to October.

  • Early movers: MDT, PVH, DG, SHLD, AAPL & more Tuesday, 2 Jun 2015 | 7:48 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • June 1- Mylan NV said Teva Pharmaceutical Industries Ltd, which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake. Teva disclosed a 1.35 percent stake in Mylan last week. Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion.

  • Early movers: BRCM, COST, EXPR, ANF & more Thursday, 28 May 2015 | 7:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • After-hours buzz: Palo Alto, Teva, Analog & more Wednesday, 27 May 2015 | 5:30 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Wednesday: Palo Alto, Teva, Analog Devices & more.

  • Teva discloses 1.35 pct stake in target Mylan Wednesday, 27 May 2015 | 4:42 PM ET

    May 27- Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV, saying the purchase underscored its commitment to buy Mylan as soon as possible. Teva proposed to buy Mylan for $82 per share, or about $43 billion, in cash and stock last month. Mylan rejected the offer saying it "grossly undervalued" the company, setting up a three-way battle...

  • May 8- A U.S. judge on Friday dismissed a lawsuit filed by the city of Chicago in federal court against four drugmakers accused of promoting painkiller addiction through deceptive marketing, though the case will continue against Oxycontin maker Purdue Pharma LP. The companies dismissed from the lawsuit are Teva Pharmaceutical Industries Ltd, Johnson&...

  • May 7- California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment. The case, which began in 2000 in California state court, centers on a series of settlements in the late 1990 s under...